Recently, it was suggested that glioneuronal tumours can be separated into two groups: one group enriched for BRAF mutations with an astrocytic expression phenotype and one group enriched for FGFR1 mutations with an oligodendrocyte precursor expression phenotype [23]. The gene discussed is FGFR1; the disease is neoplasm.